Evaluation of the Severity of Systemic Sclerosis by Nailfold Capillary Microscopy in 112 Patients

Abstract

The authors used nailfold capillary microscopy (NCM) to evaluate 112 pa tients with systemic sclerosis spectrum disorders (SSc). Patients were classified as S1 if they had skin involvement proximal to the metacarpo-phalangeal joints. S2 if they had at least two minor SSc American Rheumatism Association criteria, and S3 if they had at least two CREST criteria (calcinosis, Raynaud's, esophageal motility disorder, sclerodactyly, telangiectases), without S1 or S2 criteria. Dis ease duration from the first symptom was similar in all groups (7.17 ± 8.98 years). Disease severity was determined by a total score of seven target organ involve ments. S1 patients had a greater degree of skin and pulmonary involvement, with a mean score of 26.2 ± 17.3. S2 patients had a mean score of 13.8 ± 12.4, and had mostly vascular and digestive involvement, in comparison with S3 patients (7.2 ± 7.2; p<0.001 and p<0.01 respectively).

NCM sensitivity for S1 and S2 was 93.6%. NCM correlated with the degree of target organ involvement (p < 0.01). Three NCM profiles established were: "mild," normal or borderline capillaries; "moderate," other abnormalities with no capillary telangiectases; and "severe," abnormalities other than those of the mild profile, with capillary telangiectases.

The positive correlation observed between the degree of skin and vascular abnormalities and the severity of digestive, renal, musculoskeletal, and pulmo nary involvement permits rapid prediction of target organ involvement by SSc at the first visit.

Get full access to this article

View all access options for this article.

References

Carpentier PH , Maricq HR : Microvasculature in systemic sclerosis. In: Rheumatic Disease Clinics of North America, Scleroderma, ed. by LeRoy EC. Philadelphia: WB Saunders Company, 1990, pp 75-91.

Chen ZY , Silver RM , Ainsworth SK , et al: Association between fluorescent antinuclear antibodies, capillary pattern, and clinical features in scleroderma spectrum disorders. Am J Med 77:812-822, 1984.

Lovy M. , MacCarter D. , Steigerwald JC : Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis. Arthritis Rheum 28:496-501, 1985.

Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee : Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum 23:581-590, 1980.

Rodnan GP , Jablonska S. , Medsger TA : Classification and nomenclature of progressive systemic sclerosis (scleroderma) . Clin Rheum Dis 5:5-13, 1979.

Medsger TA , Masi AT , Rodnan GP , et al: Survival with systemic sclerosis (scleroderma): A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75:369-376, 1971.

Barnett AJ , Miller MH , Littlejohn GO : survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 15:276-283, 1988.

Peters-Golden M. , Wise RA , Hochberg MC , et al: Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 77:1027-1034, 1984.

Steen VD , Medsger TA , Rodnan GP : D-pensillamine therapy in progressive systemic sclerosis (scleroderma). Ann Intern Med 97:652-658, 1982.

10.

Marcq HR : Widefield capillary microscopy. Technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 24:1159-1165, 1981.

11.

Maricq HR , LeRoy EC , D'Angelo WA , et al: Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23:183-189, 1980.

12.

Maricq HR , Spencer-Green G. , LeRoy EC: Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis . Am J Med 61:862-870, 1976.